Comparison of effects between higher dosages of infliximab and switching to other biologics for rheumatoid arthritis patients with less responsiveness to infliximab therapy (cHAMLET)

Comparison of effects between higher dosages of infliximab and switching to other biologics for rheumatoid arthritis patients with less responsiveness to infliximab therapy (cHAMLET) - cHAMLET

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002340

Enrollment

Registered

2009-08-20

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Treatment with higher dosages of infliximab (3-10 mg/Kg) Every 2 months Follow-up to 54 weeks Treatment with one of other biologics (etanercept, adalimumab, tocilizumab) in standard protocol Follow

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose DAS28-ESR are over 3.2 (DAS28-CRP>2.7) after low-dose infliximab (3mg/Kg) therapy at least 5 times

Exclusion criteria

Exclusion criteria: Patients whose DAS28-ESR are below 3.2 (DAS28-CRP>2.7) after low-dose infliximab (3mg/Kg) therapy at least 5 times

Design outcomes

Primary

Measure	Time frame
DAS28, EULAR responsiveness	—

Secondary

Measure	Time frame
mHAQ, The number and dosages of concomitant medication	—

Countries

Japan

Contacts

Public ContactTatsuya Koike

Osaka City University Medical School Rheumatosurgery

tatsuya@med.osaka-cu.ac.jp06-6645-3984

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026